Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?

Alya Perthus; Fanny Colin; Emilie Charton; Amélie Anota; Faustine Lhomme; Guillaume Manson; Sophie De Guibert; Pierre Daufresne; Adeline Bellec; Laetitia Le Bars; Sandra De Barros; Loïc Ysebaert; Marianne Merceur; Mélanie Cogné; Thierry Lamy De La Chapelle; Roch Houot; Aline Moignet

doi:10.1002/hem3.72

Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?

Hemasphere. 2024 May 27;8(5):e72. doi: 10.1002/hem3.72. eCollection 2024 May.

Authors

Alya Perthus¹, Fanny Colin¹, Emilie Charton², Amélie Anota^{2

3}, Faustine Lhomme¹, Guillaume Manson¹, Sophie De Guibert¹, Pierre Daufresne¹, Adeline Bellec¹, Laetitia Le Bars¹, Sandra De Barros⁴, Loïc Ysebaert⁴, Marianne Merceur⁵, Mélanie Cogné⁵, Thierry Lamy De La Chapelle^{1

6}, Roch Houot^{1

6}, Aline Moignet¹

Affiliations

¹ Service d'Hématologie-CHU Pontchaillou, Department of Hematology University Hospital of Rennes Rennes France.
² Human and Social Sciences Department Leon Berard Center Lyon France.
³ Department of Clinical Research and Innovation Leon Berard Center Lyon France.
⁴ Department of Hematology Cancer University Institute of Toulouse Oncopole Toulouse France.
⁵ Department of Physical and Rehabilitation Medicine University Hospital of Rennes Rennes France.
⁶ UMR U1236, INSERM University of Rennes Rennes France.

Abstract

Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T-cell therapy. We prospectively assessed the multidimensional recovery of lymphoma patients in remission, before leukapheresis, before CAR T-cell infusion, and 3, 6, and 12 months thereafter. Validated tools were used to measure lymphoma-related and global health-related quality of life (HRQoL; Functional Assessment of Cancer Therapy-Lymphoma [FACT-Lym] and EQ-5D-5L), cognitive complaint (FACT-Cognition), fatigue (FACIT-Fatigue subscale), psychological status (Hospital Anxiety and Depression Scale, Post-Traumatic Check List Scale), and sexuality (Relationship and Sexuality Scale). Beyond 12 months of remission, we also surveyed physical, professional, sexual, and general life status. At 3, 6, and 12 months, 53, 35, and 23 patients were evaluable, respectively. Improvement in lymphoma-related HRQoL was clinically relevant at 3, 6, and 12 months with a mean change from baseline of 10.9 (95% confidence interval [CI]: 5.8; 16.1), 12.2 (95% CI: 4.2; 20.1), and 11.72 (95% CI: 2.06; 21.38), respectively. Improvement in global HRQoL, fatigue, and anxiety was clinically relevant, but 20%-40% of patients experienced persistent fatigue, psychological distress, and cognitive complaints over time. Beyond 12 months after CAR T cells, 81.8% of 22 evaluable patients were satisfied with their daily life. Physical activity, professional, sexual, and global well-being had returned to prediagnosis levels in nearly half of the patients. We found an improvement in HRQoL after CAR T-cell therapy including anxiety, depression, sexual satisfaction, and general well-being. However, not all patients recover a "normal life." Further research is needed to determine which patients are at risk of quality-of-life impairment to improve recovery after CAR T-cell infusion.